Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4290635 | 0.82 | ALDH1A1 (0.46) | PKMMAPTMEN1KMT2AGAA | |
| Hydrochloric Acid SCHEMBL4281893 | 0.80 | PKM (0.50) | PKMNPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL4281389 | 0.76 | RBP4 (0.38) | MAPTKMT2AGAA | |
| SCHEMBL4283350 | 0.73 | SCN9A (0.39) | KMT2AHCRTR2GAA | |
| SCHEMBL4295523 | 0.72 | HCRTR1 (0.36) | MAPTHCRTR2POLB | |
| SCHEMBL4281213 | 0.71 | CHRNA4 (0.38) | NPSR1MEN1KMT2A | |
| SCHEMBL4282907 | 0.71 | HCRTR1 (0.32) | HCRTR2 | |
| SCHEMBL3494366 | 0.70 | TEAD1 (0.50) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL4286428 | 0.70 | HCRTR1 (0.47) | RAB9AMAPTSMN1; SMN2HCRTR2POLB | |
| SCHEMBL4286026 | 0.70 | HPGD (0.49) | MAPTSMN1; SMN2KMT2APOLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | PKM 847/4885NPC1 1165/4885RAB9A 1247/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | PKM 847/4885NPC1 1165/4885RAB9A 1247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.